FDA Issues CRL for Alexza Pharmaceuticals' Adasuve
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) stock closed at 49 cents Friday, a loss of 12 cents, or about 20 percent, on news that the FDA had issued a complete response letter for its new drug application for Adasuve (loxapine) inhalation powder for agitation in schizophrenia and bipolar disorder.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST